JP2014517690A5 - - Google Patents

Download PDF

Info

Publication number
JP2014517690A5
JP2014517690A5 JP2014510413A JP2014510413A JP2014517690A5 JP 2014517690 A5 JP2014517690 A5 JP 2014517690A5 JP 2014510413 A JP2014510413 A JP 2014510413A JP 2014510413 A JP2014510413 A JP 2014510413A JP 2014517690 A5 JP2014517690 A5 JP 2014517690A5
Authority
JP
Japan
Prior art keywords
noc
nucleic acid
multimer
igg2ah
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014510413A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014517690A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/036975 external-priority patent/WO2012154759A2/en
Publication of JP2014517690A publication Critical patent/JP2014517690A/ja
Publication of JP2014517690A5 publication Critical patent/JP2014517690A5/ja
Pending legal-status Critical Current

Links

JP2014510413A 2011-05-09 2012-05-08 遺伝子操作した成長因子変異体 Pending JP2014517690A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161484052P 2011-05-09 2011-05-09
US61/484,052 2011-05-09
PCT/US2012/036975 WO2012154759A2 (en) 2011-05-09 2012-05-08 Genetically engineered growth factor variants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016204089A Division JP6717725B2 (ja) 2011-05-09 2016-10-18 遺伝子操作した成長因子変異体

Publications (2)

Publication Number Publication Date
JP2014517690A JP2014517690A (ja) 2014-07-24
JP2014517690A5 true JP2014517690A5 (enExample) 2015-06-25

Family

ID=47139949

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2014510413A Pending JP2014517690A (ja) 2011-05-09 2012-05-08 遺伝子操作した成長因子変異体
JP2016204089A Active JP6717725B2 (ja) 2011-05-09 2016-10-18 遺伝子操作した成長因子変異体
JP2019211946A Pending JP2020039359A (ja) 2011-05-09 2019-11-25 遺伝子操作した成長因子変異体
JP2021193554A Pending JP2022031824A (ja) 2011-05-09 2021-11-29 遺伝子操作した成長因子変異体
JP2024006988A Pending JP2024056702A (ja) 2011-05-09 2024-01-19 遺伝子操作した成長因子変異体

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2016204089A Active JP6717725B2 (ja) 2011-05-09 2016-10-18 遺伝子操作した成長因子変異体
JP2019211946A Pending JP2020039359A (ja) 2011-05-09 2019-11-25 遺伝子操作した成長因子変異体
JP2021193554A Pending JP2022031824A (ja) 2011-05-09 2021-11-29 遺伝子操作した成長因子変異体
JP2024006988A Pending JP2024056702A (ja) 2011-05-09 2024-01-19 遺伝子操作した成長因子変異体

Country Status (8)

Country Link
US (3) US20140065113A1 (enExample)
EP (1) EP2707021B1 (enExample)
JP (5) JP2014517690A (enExample)
CN (2) CN112028985A (enExample)
AU (1) AU2012253652B2 (enExample)
CA (1) CA2835453A1 (enExample)
IL (1) IL229316B (enExample)
WO (1) WO2012154759A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4086338A1 (en) 2011-03-17 2022-11-09 Minerva Biotechnologies Corporation Method for making pluripotent stem cells
EP2707021B1 (en) * 2011-05-09 2024-02-21 Minerva Biotechnologies Corporation Genetically engineered growth factor variants
KR20210082547A (ko) * 2013-02-20 2021-07-05 미네르바 바이오테크놀로지 코포레이션 Ｎｍｅ 저해제 및 ｎｍｅ 저해제의 사용 방법
EP3207369A4 (en) * 2014-10-16 2018-06-13 Counsyl, Inc. Variant caller
CA3183682A1 (en) 2020-06-26 2021-12-30 Minerva Biotechnologies Corporation Anti-nme antibody and method of treating cancer or cancer metastasis
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
CA3248038A1 (en) 2022-04-12 2023-10-19 Minerva Biotechnologies Corporation ANTI-MUC1* VARIABLE ANTIBODIES AND RELATED USES
CN117736272B (zh) * 2024-02-19 2024-04-30 四川省医学科学院·四川省人民医院 一种具有促成骨功能的生物活性多肽

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2164634T3 (es) * 1989-10-18 2002-03-01 Us Health Produccion y uso de proteina nm23-h2 humana y anticuerpos previstos a tal efecto.
US5958671A (en) * 1996-04-23 1999-09-28 Presidents And Fellows Of Harvard College Methods and compositions for regulating T cell subsets by modulating transcription factor activity
US20050112607A1 (en) * 1999-01-23 2005-05-26 Bamdad Cynthia C. Rapid and sensitive detection of protein aggregation
US7550143B2 (en) * 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
ATE407697T1 (de) * 1999-07-13 2008-09-15 Bolder Biotechnology Inc Erythropoietin immunglobulin fusionsproteine
WO2001010912A1 (en) * 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
US20020169290A1 (en) * 2000-11-02 2002-11-14 Claus Bornaes New multimeric interferon beta polypeptides
WO2002036626A1 (en) * 2000-11-02 2002-05-10 Maxygen Aps Single-chain multimeric polypeptides
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
AU2002306921A1 (en) * 2001-03-27 2002-10-08 Massachusetts Institute Of Technology Methods and products related to fgf dimerization
EP1353182A3 (en) * 2002-04-12 2004-02-04 Smithkline Beecham Corporation Method of predicting cell-based assay results using binding profiles
JP2006507256A (ja) * 2002-09-24 2006-03-02 ザ バーナム インスティチュート Ｅｐｈ受容体活性を調節する新規薬剤
US7700097B2 (en) * 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
US20050054752A1 (en) * 2003-09-08 2005-03-10 O'brien John P. Peptide-based diblock and triblock dispersants and diblock polymers
CA2553187A1 (en) * 2004-01-28 2005-08-11 Syntonix Pharmaceuticals, Inc. Heterodimeric follicle stimulating hormone-fc (fsh-fc) fusion proteins for the treatment of infertility
CN105837690A (zh) * 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
US20090075926A1 (en) * 2006-12-06 2009-03-19 Bamdad Cynthia C Method for identifying and manipulating cells
JP2011526794A (ja) * 2008-07-02 2011-10-20 エマージェント プロダクト デベロップメント シアトル， エルエルシー ＴＧＦ−βアンタゴニスト多重標的結合性分子
KR20160017117A (ko) * 2008-10-09 2016-02-15 미네르바 바이오테크놀로지 코포레이션 세포내에서 다능성을 유도하기 위한 방법
MX2011013385A (es) * 2009-06-11 2012-05-29 Minerva Biotechnologies Corp Metodos para cultivar celulas madre y celulas progenitoras.
US20130040845A1 (en) * 2010-02-16 2013-02-14 Immune Disease Institute, Inc. Method for screening receptors/ligands interactions
EP4086338A1 (en) * 2011-03-17 2022-11-09 Minerva Biotechnologies Corporation Method for making pluripotent stem cells
EP2707021B1 (en) * 2011-05-09 2024-02-21 Minerva Biotechnologies Corporation Genetically engineered growth factor variants

Similar Documents

Publication Publication Date Title
US20240279303A1 (en) Tissue-specific wnt signal enhancing molecules and uses thereof
JP7227290B2 (ja) キメラ抗原受容体、組成物及び方法
JP6965311B2 (ja) 二重特異的融合タンパク質
JP2017061471A5 (enExample)
CN102781960B (zh) Hsa相关组合物及使用方法
JP7005019B2 (ja) 組織修復のための二重特異性治療用タンパク質
JP2013541335A5 (enExample)
WO2010105573A1 (zh) 抗血管新生融合蛋白
US20240294590A1 (en) Nucleic acid encoding genetically engineered growth factor variants
JP2011525363A5 (enExample)
JP2014510518A (ja) Ｈｓａ関連組成物および使用方法
JP2017529059A5 (enExample)
WO2014178078A2 (en) Novel cloning, expression & purification method for the preparation of ranibizumab
JP7794421B2 (ja) 腫瘍を標的にする合成アデノウイルスおよびその使用
US20140234316A1 (en) Vaccibodies targeted to cross-presenting dendritic cells
JP2014510519A5 (enExample)
JP2022541761A5 (enExample)
JP2025137512A (ja) 新規に設計された共局在化依存性タンパク質スイッチを使用する超特異的細胞標的化
CN105399832A (zh) 一种无标签单链型人源双特异性抗体及其用途
CA3238005A1 (en) Chimeric antigen receptors
CN103342744B (zh) 一种血管新生蛋白及其应用
CN107298714A (zh) 一种双靶标融合蛋白及其制备方法和用途
SE0901565A1 (sv) Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi
JP2013545440A (ja) マカカ・ファシキュラリス（Ｍａｃａｃａｆａｓｃｉｃｕｌａｒｉｓ）ＣＣＬ１７
CN106908605A (zh) eLtaS蛋白作为预防和治疗胰岛素抵抗相关疾病的药物靶点的应用